NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and clinical laboratory company, announced today that its Life Sciences division has established a collaboration with Innate Pharma S.A. to support a novel application of its ProteoStat® products for antibody-drug conjugate (ADC) design. ADCs are monoclonal antibodies engineered to go unnoticed, delivering cytotoxic drugs to cells expressing the antigen target. Cancer therapy has become the most prevalent application area, with 30 ADCs currently in clinical trials. Successful development of an ADC requires optimization of several elements, including the antibody, the potency of the cytotoxic drug, the stability of the linker, the site of conjugation and the stoichiometry of the resulting adducts.
Help employers find you! Check out all the jobs and post your resume.
